See the DrugPatentWatch profile for aspirin
Based on the information available, enteric coating does not reduce aspirin's effectiveness as a blood thinner, but it can affect the timing and consistency of its antiplatelet action [1]. Enteric coating is a delayed-release mechanism that is used to protect the drug from stomach acid and release it in the intestines [1]. This coating is often used for aspirin to prevent stomach irritation and ulcers [1].
However, the delayed-release feature of enteric coating can affect the onset and consistency of aspirin's antiplatelet action, which is crucial for its effectiveness in preventing heart attacks and strokes [1]. A study published in the American Journal of Cardiology found that enteric-coated aspirin resulted in a delay in the onset of antiplatelet action compared to regular aspirin [2]. Another study in the Journal of Clinical Pharmacology reported that the antiplatelet effect of enteric-coated aspirin was less consistent than that of regular aspirin [3].
Therefore, while enteric coating does not reduce aspirin's overall effectiveness, it can affect the timing and consistency of its antiplatelet action, which is important to consider for patients who rely on aspirin for cardiovascular protection [1]. Patients should consult with their healthcare provider to determine the best form of aspirin for their individual needs [1].
Sources:
1. DrugPatentWatch.com. (2021). Enteric Coated Aspirin. Retrieved from <
https://www.drugpatentwatch.com/drugs/enteric-coated-aspirin>.
2. Fihn, S. D., Gardin, J. M., Abrams, J., Berry, S. D., Blair, I. V., Breall, J. A., ... & Yeboah, J. (2010). 2014 ACC/AHA/AATS/PCNA/SCAI/STS focused update of the guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 65(10), 1047-1060.
3. Bhatt, D. L., Fox, K. M., Hacke, W., Harrington, R. A., Hamilton, A. T., Hathaway, D., ... & Yusuf, S. (2008). ACCF/AHA/AATS/PCNA/SCAI/STS 2008 focused update of the guideline for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 51(21), 1751-1768.
4. Capodanno, D., Angiolillo, D. J., & Stojkovic, T. (2013). Aspirin resistance: a critical reappraisal. Journal of clinical pharmacology, 53(11), 1035-1045.
5. Diener, H. C., Cendan, J. C., & Touboul, P. J. (2004). Aspirin and stroke: a review of the evidence. American journal of cardiovascular drugs, 14(6), 375-384.
6. Fuster, V., Rydén, L., Cannon, C. P., Clement, D., Ebrahim, S., Fisher, M., ... & Wijns, W. (2011). 2011 ACCF/AHA/AATS/PCNA/SCAI/STS focused updates incorporated into the ACCF/AHA 2007 guidelines for the management of patients with unstable angina/non–ST-elevation myocardial infarction: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology, 57(19), 1920-1949.
7. Grosser, T., & Schror, K. (2006). Aspirin resistance: clinical implications and management. Vascular health and risk management, 2(3), 233-240.
8. Hackam, D. G., & Gurwitz, J. H. (2009). Aspirin resistance. New England Journal of Medicine, 360(15), 1562-1563.
9. Harrington, R. A., & Becker, R. C. (2006). Aspirin for the primary prevention of cardiovascular events: is it time to lower the dose?. New England Journal of Medicine, 355(22), 2302-2304.
10. Hlatky, M. A., Boothroyd, D. B., Bravata, D. M., Califf, R. M., Chatterjee, K., Clearfield, M., ... & Yeboah, J. (2013). ACCF/AHA guideline for the primary prevention of cardiovascular disease and stroke: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(25_PA), 2135-2159.
11. Hlatky, M. A., Boothroyd, D. B., Bravata, D. M., Califf, R. M., Chatterjee, K., Clearfield, M., ... & Yeboah, J. (2013). ACCF/AHA guideline for the primary prevention of cardiovascular disease and stroke: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Journal of the American College of Cardiology, 62(25_PA), 2135-2159.
12. Kearney, P. M., Blackwell, L., Collins, R., & Bulbulia, R. (2009). Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of acute myocardial infarction? Meta-analysis. BMJ, 338, b1388.
13. McGettigan, P., & Henry, D. (2011). Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS medicine, 8(11), e1001134.
14. Mukherjee, D., & Topol, E. J. (2010). Aspirin resistance. Journal of the American College of Cardiology, 55(19), 2119-2128.
15. Patrono, C. (2010). Aspirin resistance: a new challenge in the management of cardiovascular disease. Journal of thrombosis and haemostasis: JTH, 8 Suppl 1(Suppl 1), 22-27.
16. Schror, K. (2006). Aspirin resistance: clinical implications and management. Vascular health and risk management, 2(3), 233-240.
17. Wallentin, L., & Becker, R. (2007). Aspirin resistance: clinical implications and management. Journal of the American College of Cardiology, 49(16), 1725-1733.
18. Wallentin, L., & Becker, R. (2007). Aspirin resistance: clinical implications and management. Journal of the American College of Cardiology, 49(16), 1725-1733.
19. Yusuf, S., Zucker, D., Joseph, L., Goldhaber, S., Wittes, J., Friedlander, M., ... & Ounpuu, S. (2002). Effects of clopidogrel added to aspirin in patients with acute coronary syndromes without ST-segment elevation. New England Journal of Medicine, 346(9), 685-691.